Page 208 - 2022_01-Haematologica-web

T. Braun et al.
et al. A cooperative microRNA-tumor sup- pressor gene network in acute T-cell lym- phoblastic leukemia (T-ALL). Nat Genet. 2011;43(7):673-678.
36. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2013;42(D1):D68-D73.
37. Usuba W, Urabe F, Yamamoto Y, et al. Circulating miRNA panels for specific and early detection in bladder cancer. Cancer Sci. 2019;110(1):408-419.
38. Bronevetsky Y, Villarino AV, Eisley CJ, et al. T cell activation induces proteasomal degradation of Argonaute and rapid remod- eling of the microRNA repertoire. J Exp Med. 2013;210(2):417-432.
39. Sousa IG, do Almo MM, Simi KCR, et al. MicroRNA expression profiles in human CD3(+) T cells following stimulation with anti-human CD3 antibodies. BMC Res Notes. 2017;10(1):124.
40. Pomari E, Lovisa F, Carraro E, et al. Clinical impact of miR-223 expression in pediatric T-Cell lymphoblastic lymphoma. Oncotarget. 2017;8(64):107886-107898.
41. Kwon JJ, Factora TD, Dey S, Kota J. A sys- tematic review of miR-29 in cancer. Mol Ther Oncolytics. 2018;12:173-194.
42. Humphries B, Yang C. The microRNA-200 family: small molecules with novel roles in cancer development, progression and ther- apy. Oncotarget. 2015;6(9):6472-6498.
43. Garzon R, Heaphy CEA, Havelange V, et al. MicroRNA 29b functions in acute myeloid leukemia. Blood. 2009;114(26):5331-5341.
44. Feng YH, Tsao CJ. Emerging role of microRNA-21 in cancer (Review). Biomed Rep. 2016;5(4):395-402.
45. Li J, Qin Y, Zhang H. Identification of key miRNA-gene pairs in chronic lymphocytic leukemia through integrated analysis of mRNA and miRNA microarray. Oncol Lett. 2018;15(1):361-367.
46. Prinz C, Vasyutina E, Lohmann G, et al. Organometallic nucleosides induce non- classical leukemic cell death that is mito- chondrial-ROS dependent and facilitated by TCL1-oncogene burden. Mol Cancer. 2015;14:114.
47. Boidol B, Kornauth C, van der Kouwe E, et al. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolympho- cytic leukemia. Blood. 2017;130(23):2499- 2503.
48. Gomez-Arteaga A, Margolskee E, Wei MT, van Besien K, Inghirami G, Horwitz S. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolympho- cytic leukemia (T-PLL) with a JAK3 muta- tion. Leuk Lymphoma. 2019;60(7):1626- 1631.
49. Bailey NG, Elenitoba-Johnson KSJ. What is new in mature T-cell leukemias? Semin Diagn Pathol. 2020;37(1):72-78.
200
haematologica | 2022; 107(1)